Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Merck
Accenture
Cantor Fitzgerald
Healthtrust
UBS
Fish and Richardson
Cerilliant
Medtronic

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,465,660

« Back to Dashboard

Summary for Patent: 4,465,660
Title: Sustained release tablet containing at least 95 percent theophylline
Abstract:Non-disintegrating theophylline tablets having a pair of opposing substantially planar surfaces and a very thin cross-section have a high bioavailability on ingestion and a relatively steady release rate permitting a 12 hr. dosing interval for maintenance of non-toxic therapeutic blood theophylline concentrations. Excipients or tableting aids are not required, but trace amounts of a tableting lubricant are preferably included to facilitate continuous large scale production.
Inventor(s): David; Stephen T. (Evansville, IN), Brooke; Dana (Evansville, IN), Gallian; Claude E. (Evansville, IN)
Assignee: Mead Johnson & Company (Evansville, IN)
Application Number:06/451,891
Patent Claim Types:
see list of patent claims
Formulation; Dosage form; Composition;

Drugs Protected by US Patent 4,465,660

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 4,465,660

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 380789 ➤ Subscribe
Austria A202081 ➤ Subscribe
Australia 549299 ➤ Subscribe
Australia 7020581 ➤ Subscribe
Belgium 888697 ➤ Subscribe
Canada 1165241 ➤ Subscribe
Switzerland 646605 ➤ Subscribe
Cyprus 1368 ➤ Subscribe
Germany 3117756 ➤ Subscribe
Denmark 155976 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
US Army
Farmers Insurance
Express Scripts
Baxter
Fish and Richardson
Harvard Business School
Deloitte
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot